Drug intelligence / Profile preview

DST-0509

Development stage: Phase 2
Lead developer: DisperSol Technologies
Modality: Small Molecules
Administration: Oral

Overview

DST-0509 is a novel, bioavailability-enhanced oral formulation of deferasirox, an iron chelator. It is being developed for the treatment of iron overload disorders, particularly in patients with transfusion-dependent thalassemia who have shown inadequate response to standard chelation therapies such as Exjade or Jadenu. DST-0509 utilizes DisperSol Technologies' KinetiSol platform to improve the solubility and absorption of deferasirox, potentially offering superior clinical performance compared to existing formulations. The drug has completed Phase 2 clinical trials evaluating its safety, pharmacokinetics, and iron-chelating activity in this patient population[3][4][7][8].

Brand names: DST-0509DST0509DST 0509
Other names: deferasirox (DST-0509)

Beyond the preview

Go deeper on DST-0509.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DST-0509.

Explore the full profile